Publication: Astım hastalarında lökotrien reseptör antagonisti tedavisinin sağlık sonuçlarına etkilerinin değerlendirilmesi
Abstract
ASTIM HASTALARINDA LÖKOTRİEN RESEPTÖR ANTAGONİSTİ TEDAVİSİNİN SAĞLIK SONUÇLARINA ETKİLERİNİN DEĞERLENDİRİLMESİ Çalışmamızın birincil amacı astım hastalarında hastaların tedavilerine bir lökotrien reseptör antagonisti olan montelukast eklenmesiyle hastaların astım kontrol durum ve yaşam kalitelerinde gözlenen değişimlerin belirlenmesiydi. Hastaların astım kontrol durumları ACQ (Asthma Control Questionnaire -Astım Kontrol Anketi), AKT (Asthma Control Test -Astım Kontrol Testi) ve GINA (The Global Initiative for Asthma) kılavuzu kriterlerine göre değerlendirilirken, yaşam kaliteleri AQLQ (Asthma Quality of Life Questionnaire- Astım Yaşam Kalitesi Anketi) ile değerlendirildi. Çalışmanın ikincil amacı ise ACQ, AKT ve GINA kılavuzu kriterlerine göre belirlenen astım kontrol durumlarının ve FEV1 arasındaki ilişkisinin saptanmasıydı. Çalışmamızda prospektif olarak değerlendirilen 50 hastanın tedavilerine montelukast eklendikten sonra AQLQ anketinin tümünde ve ayrıca her bir skalasında (aktivite, semptom, emosyonel, çevresel) olmak üzere yaşam kalitelerinde belirgin düzelme gözlenmiştir. Bu sonuca göre astım tedavisine montelukastın eklenmesinin ve hastaların takibe alınmasının yaşam kalitesinde artışla ilişkili olabileceği önerilebilir. Hastaların AKT, ACQ ve GINA kılavuzu kriterlerine göre astım kontrol durumları arasında korelasyon gözlenirken, FEV1 ile aralarında böyle bir korelasyon bulunamamıştır. Çalışmamızdaki hastalarda çalışma başlangıcında ve montelukast kullandıkları 3 ay sonrasında belirlenen astım kontrol durumları arasında anlamlı iyileşme gözlenmiştir (p<0.05); çalışma başlangıcı ve sonrası için skorlar sırasıyla şöyledir: ACQ için 18.14 ± 7.16, 8.68 ± 6.34; AKT için 13.54 ± 4.63, 19.16 ± 4.66. Sonuç olarak astım hastalarında mevcut tedaviye montelukast eklenmesiyle astım kontrol durumunda iyileşme ve yaşam kalitesinde belirgin düzelme sağlanabileceği söylenebilir. Klinik eczacılar astım hastalarının takip ve tedavisinde daha etkin rol alarak akılcı farmakoterapiye katkıda bulunabilirler. Astım, Montelukast, Yaşam Kalitesi, Klinik Eczacı
ASSESSMENT OF THE IMPACT OF LEUKOTRIENE RECEPTOR ANTAGONIST TREATMENT ON HEALTH OUTCOMES OF ASTHMA PATİENTS The primary aim of this study is to assess the impact of addition of montelukast (a leukotriene receptor antagonist) to the ongoing asthma treatment on asthma control status and quality of life of the patients the asthma control status was assessed by ACQ (Asthma Control Questionnaire), AKT (Asthma Control Test) and according to GINA (The Global Initiative for Asthma) criteria; while the quality of life was assessed by Asthma Quality of Life Questionnaire (AQLQ). The secondary objective of this study was the evaluation of the correlation among the asthma control status assessed by the ACQ, ACT, GINA criteria and FEV1 measures. We prospectively evaluated 50 patients and the scores of the overall scale AQLQ and each sub-scale (activity, symptom, emotional, environmental) significant improved after 3 months of montelukast treatment. The quality of life of the patients was found to improve as a result of montelukast addition and therapy monitoring. Significant correlations were observed among control status assessed by ACT, ACQ and according to the GINA guidelines; however, no correlation was found among the other asthma control status measures and FEV1. In our study significant differences were observed between baseline and final measures in terms of asthma control (p<0.05); the baseline and the final measures were respectively as follows: for ACQ 18.14 ± 7.16, 8.68 ± 6.34; for AKT 13.54 ± 4.63, 19.16 ± 4.66. As a conclusion, we can suggest that the addition of montelukast to the ongoing asthma treatment improved asthma control status and the quality of life of the patients. This is suggestive that clinical pharmacists should play a more active role in the treatment and follow-up of asthma patients in order to contribute to rational pharmacotherapy. Key Words: Asthma, Montelukast, Quality of Life, Clinical Pharmacist
ASSESSMENT OF THE IMPACT OF LEUKOTRIENE RECEPTOR ANTAGONIST TREATMENT ON HEALTH OUTCOMES OF ASTHMA PATİENTS The primary aim of this study is to assess the impact of addition of montelukast (a leukotriene receptor antagonist) to the ongoing asthma treatment on asthma control status and quality of life of the patients the asthma control status was assessed by ACQ (Asthma Control Questionnaire), AKT (Asthma Control Test) and according to GINA (The Global Initiative for Asthma) criteria; while the quality of life was assessed by Asthma Quality of Life Questionnaire (AQLQ). The secondary objective of this study was the evaluation of the correlation among the asthma control status assessed by the ACQ, ACT, GINA criteria and FEV1 measures. We prospectively evaluated 50 patients and the scores of the overall scale AQLQ and each sub-scale (activity, symptom, emotional, environmental) significant improved after 3 months of montelukast treatment. The quality of life of the patients was found to improve as a result of montelukast addition and therapy monitoring. Significant correlations were observed among control status assessed by ACT, ACQ and according to the GINA guidelines; however, no correlation was found among the other asthma control status measures and FEV1. In our study significant differences were observed between baseline and final measures in terms of asthma control (p<0.05); the baseline and the final measures were respectively as follows: for ACQ 18.14 ± 7.16, 8.68 ± 6.34; for AKT 13.54 ± 4.63, 19.16 ± 4.66. As a conclusion, we can suggest that the addition of montelukast to the ongoing asthma treatment improved asthma control status and the quality of life of the patients. This is suggestive that clinical pharmacists should play a more active role in the treatment and follow-up of asthma patients in order to contribute to rational pharmacotherapy. Key Words: Asthma, Montelukast, Quality of Life, Clinical Pharmacist